NGM Biopharmaceuticals Inc
NGMDelisted Apr 5, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426332
NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 75
- Q1 2024, −8 vs. previous quarter
- 13F value
- $55.1M
- Reported value at the end of Q1 2024
- Superinvestors holding
- 0
- At the end of Q1 2024
Superinvestors holding NGM, Q1 2024
No superinvestor reported holding NGM at the end of Q1 2024.
Latest insider trades
Open-market purchases and sales by NGM Biopharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2023 (view filing)4:33 PM ET | Nov 15-16 | 2 days | Column Group L P and 1 otherDirector, 10% Owner | PPurchase | +22.6K | $0.6852 | +$15.5K | +2.4%949.9K after | 2 lotsDuplicate filing |
| Nov 17, 2023 (view filing)4:30 PM ET | Nov 15-16 | 2 days | Column Group L P and 9 othersDirector, 10% Owner | PPurchase | +22.6K | $0.6852 | +$15.5K | +2.4%949.9K after | 2 lotsDuplicate filing |
| Nov 17, 2023 (view filing)4:28 PM ET | Nov 15-16 | 2 days | Column Group L P and 9 othersDirector, 10% Owner | PPurchase | +22.6K | $0.6852 | +$15.5K | +2.4%949.9K after | 2 lots |
| Nov 17, 2023 (view filing) | Nov 15-16 | 2 days | Goeddel David VDirector, 10% Owner | PPurchase | +4.18K | $0.6786 | +$2.84K | +3.2%134.2K after | 2 lots |
| Nov 17, 2023 (view filing) | Nov 15-16 | 2 days | Goeddel David VDirector, 10% Owner | PPurchase | +22.6K | $0.6868 | +$15.5K | +2.4%949.9K after | 2 lots |
| Feb 1, 2023 (view filing)4:50 PM ET | Jan 30-31 | 2 days | Column Group L P and 9 othersDirector, 10% Owner | PPurchase | +184.3K | $5.00 | +$921.1K | +24.8%927.2K after | 2 lotsDuplicate filing |
| Feb 1, 2023 (view filing)4:31 PM ET | Jan 30-31 | 2 days | Column Group L P and 1 otherDirector, 10% Owner | PPurchase | +184.3K | $5.00 | +$921.1K | +24.8%927.2K after | 2 lotsDuplicate filing |
| Feb 1, 2023 (view filing)4:29 PM ET | Jan 30-31 | 2 days | Column Group L P and 9 othersDirector, 10% Owner | PPurchase | +184.3K | $5.00 | +$921.1K | +24.8%927.2K after | 2 lots |
| Feb 1, 2023 (view filing) | Jan 30-31 | 2 days | Goeddel David VDirector, 10% Owner | PPurchase | +184.3K | $5.00 | +$921.4K | +24.8%927.2K after | 2 lots |
| Jan 25, 2023 (view filing)4:38 PM ET | Jan 23 | 2 days | Column Group L P and 1 otherDirector, 10% Owner | PPurchase | +9.90K | $5.00 | +$49.5K | +1.4%743.0K after | Duplicate filing |
Top 10 13F holders, Q1 2024
The largest institutional positions in NGM Biopharmaceuticals Inc at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| The Column Group LLC | 18,136,735 | $28.8M | 17.96% | 00.0% | Unchanged |
| BlackRock Inc. | 3,004,210 | $4.78M | 0.00% | −173,955−5.5% | Reduced |
| Vanguard Group Inc | 2,324,392 | $3.70M | 0.00% | −446,182−16.1% | Reduced |
| StepStone Group LP | 1,573,357 | $2.50M | 0.53% | 00.0% | Unchanged |
| Euclidean Capital LLC | 992,168 | $1.58M | 0.20% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 983,836 | $1.56M | 0.00% | +62,226+6.8% | Added |
| Trium Capital LLP | 977,965 | $1.55M | 0.58% | +977,965 | New |
| State Street Corp | 823,111 | $1.31M | 0.00% | +712+0.1% | Added |
| ADAR1 Capital Management, LLC | 816,581 | $1.30M | 0.35% | +816,581 | New |
| Renaissance Technologies LLC | 611,300 | $972.0K | 0.00% | −145,592−19.2% | Reduced |